Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

BETIMOL

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A medicine brand in Osaka, Japan. The asset is a prescription eye drop medicine used to reduce pressure inside the eye in patients with ocular hypertension or open-angle glaucoma. The primary ingredient of the asset is timolol hemihydrate and is available in concentrations of 0.25% and 0.5%.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • Osaka
  • Japan

BETIMOL Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore BETIMOL‘s full profile, request access.

Request full access to PitchBook

BETIMOL Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore BETIMOL‘s full profile, request access.

Request full access to PitchBook